Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
AXDX Accelerate Diagnostics
1.520
-0.020-1.30%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-46.9% 212.5641 -48.9% 214.2239 -49.86% 225.145 -49.86% 225.145
Receivable Turnover(T)
3.08% 5.2628 34.88% 5.9765 30.12% 6.0889 30.12% 6.0889
Inventory Turnover(T)
121.91% 1.8466 116.02% 1.661 119.37% 1.7031 119.37% 1.7031
Fixed Assets Turnover(T)
28.31% 1.5438 40.36% 1.5008 29.57% 1.3686 29.57% 1.3686
Total Asset Rate(T)
51.22% 0.174 40.58% 0.1499 36.25% 0.1335 36.25% 0.1335
ROA
-4.33% -83.524% -8.76% -82.991% -28.28% -88.062% -28.28% -88.062%
Efficiency Ratios
ROA 5 Year Average
-- -- -- -- -9.46% -65.550% -- --
Profitability Ratios TTM
Gross Margin
-109.22% -3.379% -110.27% -3.895% -108.1% -3.234% -108.1% -3.234%
Operating Margin
9.63% -510.522% 5.2% -551.694% -6.46% -607.367% -6.46% -607.367%
Net Margin
31.01% -480.032% 22.64% -553.494% 5.85% -659.497% 5.85% -659.497%
EBITDA Margin
27.13% -3.9229% 21.48% -4.3165% 5.34% -5.0581% 5.34% -5.0581%
R & D Expense Ratio
-8.71% 172.470% -12.35% 172.410% -2.17% 186.240% -2.17% 186.240%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Current Ratio
-50.12% 4.481 -33.03% 7.4399 -10.25% 10.5588 -10.25% 10.5588
Quick Ratio
-51.38% 3.7023 -31.46% 6.3903 -5.23% 9.4943 -5.23% 9.4943
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -28.81% 27.608% -- --
Revenue CAGR(5Y)
-- -- -- -- -15.21% 116.799% -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
CEO: Phillips, Jack
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top